ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1554

Longitudinal Trajectories of the Weighted Lansbury Articular Indices and Standard Joint Counts Are Similarly Correlated with Trajectories of Physical Function in Early Inflammatory Arthritis

Siok Hoon Lily Lim1, Susan J. Bartlett2, Gilles Boire3, Boulos Haraoui4, Edward Keystone5, J Carter Thorne6, Janet E. Pope7, Diane Tin8, Vivian P. Bykerk9, Carol Hitchon10 and Canadian Early Arthritis Cohort (CATCH), 1Pediatrics, University of MAnitoba, Winnipeg, MB, Canada, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, 4Institute de Rheumatologie, Montreal, QC, Canada, 5Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, 6Southlake Regional Health Centre, Newmarket, ON, Canada, 7University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 8The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 9Divison of Rheumatology, Hospital for Special Surgery, New York, NY, 10University of Manitoba, Winnipeg, MB, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Early Rheumatoid Arthritis and outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Residual disease activity impacts functional status and quality of life (QoL) in patients with early rheumatoid arthritis (ERA). Large weight bearing joints are more likely to impact function such as walking than small non-weight bearing joints although the effect may be task dependent.  The Lansbury Articular Index (LAI) weights large joints more than small joints thus may give a better estimate of overall disease burden with respect to large joint function.  The Health Assessment Questionnaire (HAQ) seems to weigh upper extremity tasks more than lower extremity or weight bearing tasks.  In a large multicenter cohort of ERA patients, we therefore sought to determine associations of LAI with HAQ, QoL and baseline disability status and whether changes in the LAI trajectory more closely reflected the evolution of the HAQ trajectory than the standard joint count measures.

Methods: We used data from subjects with ERA (less than 1 year symptom duration at first visit) followed in a multicentre Early Arthritis Cohort.  Arthritis activity measures (DAS28, tender 28 joint count (tjc28), swollen 28 joint count (sjc28), function (Health Assessment questionnaire; HAQ) QoL (SF12 physical (PCS) and mental (MCS) indices) and work status were captured per study protocol.  The LAI based on 28 joints was calculated separately for swollen (LS28) and tender (LT28) joint counts.  The impact of LS28, LT28 on baseline disability status was modeled using logistic regression. Individuals’ trajectories for each measure (HAQ, DAS28, TJC28, SJC28, LT28,LS28) were visualized with LOESS  plots and marginal trajectories by variable plotted. Each measure’s longitudinal trajectory was fitted using the best fitting fractional polynomials. Each individual disease activity trajectory was then jointly modelled with the HAQ longitudinally (joint modelling). Correlations between each pair of joint trajectories (HAQ with TJC28 or SJC28 or LT28 or LS28) were calculated.

Results: ERA subjects (n=2133, 73% female; baseline mean (SD) Age 53(15) years, DAS 5.1(1.4)) were followed for median (IQR) 24(10,48) months. At last visit 44 % were in remission (DAS28<2.6). Combining all visits, the LS28 strongly correlated with SJC28 (r= 0.9 p<0.0001), PCS (r=-0.4 p<0.0001) and HAQ (r= 0.4 p<0.0001).  The LT28 correlated with the TJC28 (0.9 p<0.001), PCS (r=-0.5 p<0.0001) and HAQ (0.5 p<0.0001). Correlations were even stronger with the full LAI (42 joints).  Disability or sick leave at baseline (6% of cohort) was associated with higher LT28 (OR 1.003 p=0.001) and higher TJC28 (OR 1.071 p<0.0001) in separate logistic regression models that included age.  The HAQ trajectory was highly correlated with the trajectories for DAS28 (r=0.83), LT28 (r=0.83), and TJC28 (r=0.85) and less strongly with trajectories for LS28(r= 0.59) and SJC28 (r=0.61).

Conclusion: The trajectories of function (HAQ) and both Lansbury and standard joint counts are highly correlated over time in ERA. The LAI performed similarly to standard joint counts which are easier to determine.  Although type of occupation was not addressed and likely influences the impact of lower extremity involvement, both LT28 and TJ28 associated with baseline work disability.     

 


Disclosure: S. H. L. Lim, None; S. J. Bartlett, None; G. Boire, None; B. Haraoui, None; E. Keystone, Abbott, Amgen, AstraZeneca, BMS, Hoffman-LaRoche, Janssen, Eli Lilly and Company, Novartis, Pfizer, Sanofi-Aventis, UCB, 2,Abbott, AstraZeneca, Biotest, BMS, Crescendo, Hoffmann-LaRoche, Genentech, Janssen, Eli Lilly and Company, Merck, Pfizer, UCB, 5,Abbott, AstraZeneca, BMS Canada, Hoffmann-LaRoche, Janssen, Pfizer, UCB, Amgen, 9; J. C. Thorne, abbvie, 5,Amgen, 5,AstraZeneca, 5,Bristol-Myers Squibb, 5,Centocor, Inc., 5,Celgene, 5,Genzyme Corporation, 5,hospira, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,Genzyme Corporation, 8,Medac Pharma, 8,Antares, 8,Abbvie, 2,Amgen, 2,AstraZeneca, 2,Celgene, 2,Eli Lilly and Company, 2,Novartis Pharmaceutical Corporation, 2,Pfizer Inc, 2; J. E. Pope, AbbVie, Actelion, Amgen, BMS, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, UCB, 5; D. Tin, None; V. P. Bykerk, AbbVie, Bristol-Myers Squibb, Pfizer, Roche/Genentech, Regeneron, and UCB Pharma, 5; C. Hitchon, None.

To cite this abstract in AMA style:

Lim SHL, Bartlett SJ, Boire G, Haraoui B, Keystone E, Thorne JC, Pope JE, Tin D, Bykerk VP, Hitchon C. Longitudinal Trajectories of the Weighted Lansbury Articular Indices and Standard Joint Counts Are Similarly Correlated with Trajectories of Physical Function in Early Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/longitudinal-trajectories-of-the-weighted-lansbury-articular-indices-and-standard-joint-counts-are-similarly-correlated-with-trajectories-of-physical-function-in-early-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-trajectories-of-the-weighted-lansbury-articular-indices-and-standard-joint-counts-are-similarly-correlated-with-trajectories-of-physical-function-in-early-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology